El paradigma de dOCUMENTA (13) a partir de la voz de Enrique Vila-Matas

Partiendo de la idea de dispositivo foucaultiano como una red de elementos heterogeneos, relacionados entre sí para configurar un saber que determina los efectos de verdad y realidad3, analizaremos el papel que juega el comisario, el espectador y el artista en la exposición como dispositivo de conocimiento que promulga nuevos sentidos para la verdad y la realidad. Esta alteración del dispositivo político se debe a la similitud que existe entre la exposición y los modelos de comunicación. Toda exposición artística, entendida como dispositivo de conocimiento, consiste en la disposición de objetos artísticos -materiales o inmateriales-articulados (canal) por el comisario (emisor) para hacerlos dialogar con el espectador (receptor) y generar un sentido ulterior (destino). La estructura final ofrece distintos tipos de acercamientos o lecturas determinadas por los planos desde los que se accede, y éstos, son conformados a su vez por la intención del curador y el discurso que pone en juego de los artistas expuestos. Así, el espectador que participa de esta acción comunicativa, abrirá un campo de posibilidades en las que operará su pensamiento para extraer reflexiones propias, nuevos sentidos que hará circular en la esfera pública infiriendo en la intersubjetividad –conjunto de saberes individuales que los sujetos comparten al pertenecer a una misma comunidad-. Basándonos en dOCUMENTA 13 (Kassel 2012) como paradigma de dispositivo expositivo, debido a su carácter heterogeneo y relacional, analizaremos las intenciones de la curadora, Carolyn Christov-Bakargiev, desde las impresiones de Enrique Vila-Matas recogidas en su obra Kassel no invita a la lógica. El autor nos servirá de figura transversal como espectador, cerrando así el triángulo compuesto por la comisaria de d(13), las obras seleccionadas por Vila-Matas y los saberes que adquiere como receptor de la exposición..

A new neutron monitor at the Juan Carlos I Spanish Antarctic Station (Livingston Island-Antarctic Peninsula)

Last January 2019, a new neutron monitor was installed at Juan Carlos I Spanish Antarctic Station (62º 39’ 46’’ S, 60º23’20’’ W, 12 m asl) located in Livingston Island (South Shetland Archipelago) close to the Antarctic Peninsula. The vertical rigidity cut-off for this new station is estimated as 3.52 GV. This new station (ORC) is composed of a BF3-based 3NM64 (ORCA) and 3 bare BF3 counters (ORCB). The neutron monitor is complemented by a muon telescope sharing a common room in a single stack. ORCA and ORCB with the Castilla-La Mancha neutron monitor (CaLMa) are the Spanish contributions to the Neutron Monitor Data Base. Because Juan Carlos I station is a summer station, one minute data is providing once a day during the Antarctic summer. One hour data are sent once a day during Antarctic winter. First measurements and future plans are provided in this work

Cosmic ray observations from Livingston Island

ORCA, from the Spanish name Observatorio de Rayos Cósmicos Antártico, is a cosmic ray detector devoted to the observation of secondary cosmic rays at Juan Carlos I Spanish Antarctic Base (62° 39′ 46″ S, 60° 23′ 20″ W, 12 m above sea level). ORCA was installed at the beginning of January 2019 after performing a latitudinal survey from Vigo (Spain) to Livingston Island aboard the Sarmiento de Gamboa Research Vessel. ORCA was in commissioning phase from January 2019 to March 2020, being in normal operation mode from March 2020. A vertical cutoff rigidity of 2.37GV has been computed at ORCA location and during the first year of operation, i. e. from March 2020 to March 2021. ORCA consists of three detectors stacked in a shared structure that maintains the relative distances between the detectors. A muon telescope (ORCM), a neutron monitor without any shielding around (ORCB) and a 3NM64 neutron monitor (ORCA). This configuration allows the measurement of neutron count rates at two different energy thresholds, muon count rate and muon incident directions. Measurements recorded during the first year of operation and ORCA potential capabilities are shown in this work.Agencia Estatal de Investigació

Towards a new quality-controlled daily climate dataset for the Pyrenees, 1950-2015

Póster presentado en: EMS Annual Meeting: European Conference for Applied Meteorology and Climatology celebrado del 4 al 8 de septiembre de 2017 en Dublin, IrlandaPrevious works using lower-density datasets addressed warming rates with slight differences depending on the season and diffuse trends for precipitation. New and more accurate results in spatio-temporal variations of these climate variables are expected on behalf the development of the CLIM’PY project, which aims to: i) detect past trends with instrumental data and, ii) estimate future behaviours in climatic variables based on projected scenarios. Temperature, precipitation and snow cover in the Pyrenees will be analysed within the framework of the project. In this communication, we present the methodology we will follow to conduct the quality control analysis of daily temperature and precipitation, which will include 673 stations of Spain, France and Andorra, covering the period 1950-2015

New daily quality-controlled data base for the Pyrenees (1950-2015)

Presentación realizada para el: EMS Annual Meeting - European Conference for Applied Meteorology and Climatology 2018, celebrado en Budapest del 3 al 7 de septiembre de 2018

Observed climatic trends in the Pyrenees (1950-2015)

Póster presentado en: EGU General Assembly 2019 celebrada del 7 al 12 de abril en Viena, Austria

Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain

Background Multisystem inflammatory syndrome temporally associated with COVID-19 (MIS-C) has been described as a novel and often severe presentation of SARS-CoV-2 infection in children. We aimed to describe the characteristics of children admitted to Pediatric Intensive Care Units (PICUs) presenting with MIS-C in comparison with those admitted with SARS-CoV-2 infection with other features such as COVID-19 pneumonia. Methods A multicentric prospective national registry including 47 PICUs was carried out. Data from children admitted with confirmed SARS-CoV-2 infection or fulfilling MIS-C criteria (with or without SARS-CoV-2 PCR confirmation) were collected. Clinical, laboratory and therapeutic features between MIS-C and non-MIS-C patients were compared. Results Seventy-four children were recruited. Sixty-one percent met MIS-C definition. MIS-C patients were older than non-MIS-C patients (p = 0.002): 9.4 years (IQR 5.5-11.8) vs 3.4 years (IQR 0.4-9.4). A higher proportion of them had no previous medical history of interest (88.2% vs 51.7%, p = 0.005). Non-MIS-C patients presented more frequently with respiratory distress (60.7% vs 13.3%, p < 0.001). MIS-C patients showed higher prevalence of fever (95.6% vs 64.3%, p < 0.001), diarrhea (66.7% vs 11.5%, p < 0.001), vomits (71.1% vs 23.1%, p = 0.001), fatigue (65.9% vs 36%, p = 0.016), shock (84.4% vs 13.8%, p < 0.001) and cardiac dysfunction (53.3% vs 10.3%, p = 0.001). MIS-C group had a lower lymphocyte count (p < 0.001) and LDH (p = 0.001) but higher neutrophil count (p = 0.045), neutrophil/lymphocyte ratio (p < 0.001), C-reactive protein (p < 0.001) and procalcitonin (p < 0.001). Patients in the MIS-C group were less likely to receive invasive ventilation (13.3% vs 41.4%, p = 0.005) but were more often treated with vasoactive drugs (66.7% vs 24.1%, p < 0.001), corticosteroids (80% vs 44.8%, p = 0.003) and immunoglobulins (51.1% vs 6.9%, p < 0.001). Most patients were discharged from PICU by the end of data collection with a median length of stay of 5 days (IQR 2.5-8 days) in the MIS-C group. Three patients died, none of them belonged to the MIS-C group. Conclusions MIS-C seems to be the most frequent presentation among critically ill children with SARS-CoV-2 infection. MIS-C patients are older and usually healthy. They show a higher prevalence of gastrointestinal symptoms and shock and are more likely to receive vasoactive drugs and immunomodulators and less likely to need mechanical ventilation than non-MIS-C patients

Loss of 5hmC identifies a new type of aberrant DNA hypermethylation in glioma

Aberrant DNA hypermethylation is a hallmark of cancer although the underlying molecular mechanisms are still poorly understood. To study the possible role of 5-hydroxymethylcytosine (5hmC) in this process we analyzed the global and locus-specific genome-wide levels of 5hmC and 5-methylcytosine (5mC) in human primary samples from 12 non-tumoral brains and 53 gliomas. We found that the levels of 5hmC identified in non-tumoral samples were significantly reduced in gliomas. Strikingly, hypo-hydroxymethylation at 4627 (9.3%) CpG sites was associated with aberrant DNA hypermethylation and was strongly enriched in CpG island shores. The DNA regions containing these CpG sites were enriched in H3K4me2 and presented a different genuine chromatin signature to that characteristic of the genes classically aberrantly hypermethylated in cancer. As this 5mC gain is inversely correlated with loss of 5hmC and has not been identified with classical sodium bisulfite-based technologies, we conclude that our data identifies a novel 5hmC-dependent type of aberrant DNA hypermethylation in glioma.This work has been financially supported by: the Plan Nacional de I+D+I 2013–2016/FEDER (PI15/00892 to M.F.F. and A.F.F.; RTC-2015-3393-1 to A.F.F.); the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación, and the Plan Nacional de I+D+I 2008–2011/FEDER (CP11/00131 to A.F.F.); IUOPA (to G.F.B. and M.S); the Fundación Científica de la AECC (to R.G.U.); the Fundación Ramón Areces (to M.F.F); FICYT (to E.G.T., M.G.G. and A.C.); and the Asturias Regional Government (GRUPIN14-052 to M.F.F.). Work in P.M. laboratory is supported by the European Research Council (CoG-2014-646903), the Spanish Ministry of Economy-Competitiveness (SAF-SAF2013-43065), the Obra Social La Caixa-Fundaciò Josep Carreras, and the Generalitat de Catalunya. P.M. is an investigator in the Spanish Cell Therapy cooperative network (TERCEL). The IUOPA is supported by the Obra Social Cajastur-Liberbank, Spain.Peer reviewe

Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain

Background Multisystem inflammatory syndrome temporally associated with COVID-19 (MIS-C) has been described as a novel and often severe presentation of SARS-CoV-2 infection in children. We aimed to describe the characteristics of children admitted to Pediatric Intensive Care Units (PICUs) presenting with MIS-C in comparison with those admitted with SARS-CoV-2 infection with other features such as COVID-19 pneumonia. Methods A multicentric prospective national registry including 47 PICUs was carried out. Data from children admitted with confirmed SARS-CoV-2 infection or fulfilling MIS-C criteria (with or without SARS-CoV-2 PCR confirmation) were collected. Clinical, laboratory and therapeutic features between MIS-C and non-MIS-C patients were compared. Results Seventy-four children were recruited. Sixty-one percent met MIS-C definition. MIS-C patients were older than non-MIS-C patients (p = 0.002): 9.4 years (IQR 5.5–11.8) vs 3.4 years (IQR 0.4–9.4). A higher proportion of them had no previous medical history of interest (88.2% vs 51.7%, p = 0.005). Non-MIS-C patients presented more frequently with respiratory distress (60.7% vs 13.3%, p < 0.001). MIS-C patients showed higher prevalence of fever (95.6% vs 64.3%, p < 0.001), diarrhea (66.7% vs 11.5%, p < 0.001), vomits (71.1% vs 23.1%, p = 0.001), fatigue (65.9% vs 36%, p = 0.016), shock (84.4% vs 13.8%, p < 0.001) and cardiac dysfunction (53.3% vs 10.3%, p = 0.001). MIS-C group had a lower lymphocyte count (p < 0.001) and LDH (p = 0.001) but higher neutrophil count (p = 0.045), neutrophil/lymphocyte ratio (p < 0.001), C-reactive protein (p < 0.001) and procalcitonin (p < 0.001). Patients in the MIS-C group were less likely to receive invasive ventilation (13.3% vs 41.4%, p = 0.005) but were more often treated with vasoactive drugs (66.7% vs 24.1%, p < 0.001), corticosteroids (80% vs 44.8%, p = 0.003) and immunoglobulins (51.1% vs 6.9%, p < 0.001). Most patients were discharged from PICU by the end of data collection with a median length of stay of 5 days (IQR 2.5–8 days) in the MIS-C group. Three patients died, none of them belonged to the MIS-C group. Conclusions MIS-C seems to be the most frequent presentation among critically ill children with SARS-CoV-2 infection. MIS-C patients are older and usually healthy. They show a higher prevalence of gastrointestinal symptoms and shock and are more likely to receive vasoactive drugs and immunomodulators and less likely to need mechanical ventilation than non-MIS-C patients

Integrative methylome-transcriptome analysis unravels cancer cell vulnerabilities in infant MLL-rearranged B cell acute lymphoblastic leukemia

B cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer. As predicted by its prenatal origin, infant B-ALL (iB-ALL) shows an exceptionally silent DNA mutational landscape, suggesting that alternative epigenetic mechanisms may substantially contribute to its leukemogenesis. Here, we have integrated genome-wide DNA methylome and transcriptome data from 69 patients with de novo MLL-rearranged leukemia (MLLr) and non-MLLr iB-ALL leukemia uniformly treated according to the Interfant-99/06 protocol. iB-ALL methylome signatures display a plethora of common and specific alterations associated with chromatin states related to enhancer and transcriptional control in normal hematopoietic cells. DNA methylation, gene expression, and gene coexpression network analyses segregated MLLr away from non-MLLr iB-ALL and identified a coordinated and enriched expression of the AP-1 complex members FOS and JUN and RUNX factors in MLLr iB-ALL, consistent with the significant enrichment of hypomethylated CpGs in these genes. Integrative methylome-transcriptome analysis identified consistent cancer cell vulnerabilities, revealed a robust iB-ALL–specific gene expression–correlating dmCpG signature, and confirmed an epigenetic control of AP-1 and RUNX members in reshaping the molecular network of MLLr iB-ALL. Finally, pharmacological inhibition or functional ablation of AP-1 dramatically impaired MLLr-leukemic growth in vitro and in vivo using MLLr-iB-ALL patient–derived xenografts, providing rationale for new therapeutic avenues in MLLr-iB-ALL.We thank CERCA/Generalitat de Catalunya (SGR180) and Fundació Josep Carreras-Obra Social la Caixa for their institutional support. Financial support for this work was obtained from the European Research Council (CoG-2014-646903 and PoC-2018-811220 to PM), the Spanish Ministry of Economy and Competitiveness (SAF-2019-108160-R and SAF2016-76758-R to PM and IV, respectively), the Spanish Association against cancer (AECC-CI-2015 and PROYE18061FERN to CB and MFF), the Fundación Uno entre Cienmil (to PM), the Health Institute Carlos III (ISCIII/FEDER, PI17/01028, PI15/00892, PI18/01527 to CB and AFF/MFF, respectively). We also acknowledge the Plan de Ciencia, Tecnología e Innovación from the Asturias Government cofunding 2018–2022/FEDER (IDI/2018/146to MFF). MFF also acknowledges funding from Fundación General CSIC (0348_CIE_6_E). PM also acknowledges financial support from Fundación Leo Messi. JRT and MV are supported by Juan de la Cierva fellowships by the Spanish Ministry of Science and Innovation (FJCI-2015-26965, IJC2018-36825-I, IJCI-2017-3317) and IUOPA-ISPA-FINBA (The IUOPA is supported by the Obra Social Cajastur-Liberbank, Spain). RTR is supported by a fellowship from the AECC scientific foundation. RFP and PSO are supported by the Severo Ochoa program (BP17-114 and BP17-165, respectively).Peer reviewe